Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
diabetes
4
×
life sciences
national blog main
new york blog main
4
×
san diego blog main
amarin
boston blog main
boston top stories
clinical trials
indiana blog main
investing
lifesci venture partners
medical device
merck
national top stories
new york top stories
raleigh-durham blog main
san diego top stories
san francisco blog main
seattle blog main
startups
type 1 diabetes
vascepa
venture capital
abeona therapeutics
accent therapeutics
achilles therapeutics
akouos
alder biopharmaceuticals
alexion pharmaceuticals
alnylam pharmaceuticals
alopecia areata
amgen
aphelion capital
aridis pharmaceuticals
aristea therapeutics
arrowmark partners
attack
autoimmune diseases
What
diabetes
medical
million
new
patients
startup
abuzz
adds
advance
advantages
ago
amarin
bar
based
beta
big
bio
biolinq
bionics
biosensor
blood
brings
clinical
closed
community
deeper
developing
device
dive
doctors
driven
drug
eager
expect
fish
gamble
gives
glucose
heads
including
Language
unset
Current search:
diabetes
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
